BIOMAT Database Logo BIOMAT Database Logo

Biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass. 1997

K Kagisaki, and T Masai, and K Kadoba, and Y Sawa, and F Nomura, and N Fukushima, and H Ichikawa, and T Ohata, and K Suzuki, and S Taketani, and H Matsuda
First Department of Surgery, Osaka University Medical School, Japan.

In this study, we evaluated the biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass (CPB). Eight patients were divided into 2 groups: the control group (Group C) and heparin-coated group (Group H). In Group H, CPB circuits, including the arterial pump, oxygenator, and cannulas were heparin-coated. Before, during, and after CPB, blood samples were obtained to assess the platelet counts (Plat), alpha 2-plasmin plasminogen inhibitor complex (PIC), thrombin-antithrombin III complex (TAT), C3 activation products (C3a), interleukin (IL)-6, IL-8, and polymorphonuclear neutrophil leukocyte (PMN) elastase. There was no significant difference in Plat, PIC, or TAT between groups. Group H showed significantly low levels of C3a (during and after CPB), PMN elastase (during CPB), and IL-6 (after CPB). These data demonstrated that in pediatric CPB, heparin-coated CPB circuits reduced the activation of complements and the production of PMN elastase and IL-6, suggesting the superior biocompatibility of the heparin-coated circuits.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D010107 Oxygenators, Membrane Devices in which blood and oxygen are separated by a semipermeable membrane, generally of Teflon or polypropylene, across which gas exchange occurs. The membrane may be arranged as a series of parallel plates or as a number of hollow fibers; in the latter arrangement, the blood may flow inside the fibers, which are surrounded by gas, or the blood may flow outside the fibers and the gas inside the fibers. (Dorland, 28th ed) Membrane Oxygenator,Membrane Oxygenators,Oxygenator, Membrane
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D002315 Cardiopulmonary Bypass Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs. Heart-Lung Bypass,Bypass, Cardiopulmonary,Bypass, Heart-Lung,Bypasses, Cardiopulmonary,Bypasses, Heart-Lung,Cardiopulmonary Bypasses,Heart Lung Bypass,Heart-Lung Bypasses
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females

Related Publications

K Kagisaki, and T Masai, and K Kadoba, and Y Sawa, and F Nomura, and N Fukushima, and H Ichikawa, and T Ohata, and K Suzuki, and S Taketani, and H Matsuda
Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass.
January 1994, Scandinavian journal of thoracic and cardiovascular surgery,
K Kagisaki, and T Masai, and K Kadoba, and Y Sawa, and F Nomura, and N Fukushima, and H Ichikawa, and T Ohata, and K Suzuki, and S Taketani, and H Matsuda
Heparin-coated bypass circuits in cardiopulmonary bypass: improved biocompatibility or not.
April 1996, International journal of cardiology,
K Kagisaki, and T Masai, and K Kadoba, and Y Sawa, and F Nomura, and N Fukushima, and H Ichikawa, and T Ohata, and K Suzuki, and S Taketani, and H Matsuda
Superior biocompatibility of heparin-bonded circuits in pediatric cardiopulmonary bypass.
December 1999, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi,
K Kagisaki, and T Masai, and K Kadoba, and Y Sawa, and F Nomura, and N Fukushima, and H Ichikawa, and T Ohata, and K Suzuki, and S Taketani, and H Matsuda
Heparin-coated cardiopulmonary bypass circuits.
April 1994, Journal of cardiothoracic and vascular anesthesia,
K Kagisaki, and T Masai, and K Kadoba, and Y Sawa, and F Nomura, and N Fukushima, and H Ichikawa, and T Ohata, and K Suzuki, and S Taketani, and H Matsuda
Improved blood cellular biocompatibility with heparin coated circuits during cardiopulmonary bypass.
June 2000, The Journal of cardiovascular surgery,
K Kagisaki, and T Masai, and K Kadoba, and Y Sawa, and F Nomura, and N Fukushima, and H Ichikawa, and T Ohata, and K Suzuki, and S Taketani, and H Matsuda
Improving cardiopulmonary bypass: heparin-coated circuits.
December 2003, The journal of extra-corporeal technology,
K Kagisaki, and T Masai, and K Kadoba, and Y Sawa, and F Nomura, and N Fukushima, and H Ichikawa, and T Ohata, and K Suzuki, and S Taketani, and H Matsuda
Biocompatibility reflected by haemostasis variables during cardiopulmonary bypass using heparin-coated circuits.
August 1997, The Thoracic and cardiovascular surgeon,
K Kagisaki, and T Masai, and K Kadoba, and Y Sawa, and F Nomura, and N Fukushima, and H Ichikawa, and T Ohata, and K Suzuki, and S Taketani, and H Matsuda
A prospective randomized trial comparing the clinical effectiveness and biocompatibility of heparin-coated circuits and PMEA-coated circuits in pediatric cardiopulmonary bypass.
April 2016, Perfusion,
K Kagisaki, and T Masai, and K Kadoba, and Y Sawa, and F Nomura, and N Fukushima, and H Ichikawa, and T Ohata, and K Suzuki, and S Taketani, and H Matsuda
Clinical study of biocompatibility between open and closed heparin-coated cardiopulmonary bypass circuits.
January 2003, Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs,
K Kagisaki, and T Masai, and K Kadoba, and Y Sawa, and F Nomura, and N Fukushima, and H Ichikawa, and T Ohata, and K Suzuki, and S Taketani, and H Matsuda
Heparin-coated cardiopulmonary bypass circuits in coronary bypass surgery.
August 1996, Artificial organs,
Copied contents to your clipboard!